https://www.biospace.com/psychedelics Psychedelics en-US Thu, 18 Jun 2026 13:27:51 GMT https://www.biospace.com/press-releases/paradigm-clinical-research-opens-psychedelic-research-suite-in-redding-california New specialized treatment site expands Paradigm's capabilities for psychiatric clinical trials and studies evaluating investigational psychedelic-assisted therapies Thu, 18 Jun 2026 13:27:51 GMT https://www.biospace.com/press-releases/paradigm-clinical-research-opens-psychedelic-research-suite-in-redding-california https://www.biospace.com/press-releases/delix-therapeutics-study-demonstrates-that-the-non-hallucinogenic-neuroplastogen-zalsupindole-promotes-neuroplasticity-like-ketamine-and-psychedelics Fri, 17 Oct 2025 06:59:37 GMT https://www.biospace.com/press-releases/delix-therapeutics-study-demonstrates-that-the-non-hallucinogenic-neuroplastogen-zalsupindole-promotes-neuroplasticity-like-ketamine-and-psychedelics https://www.biospace.com/press-releases/psilera-inc-atai-life-sciences-announce-licensing-agreement-for-dmt-patent-portfolio Fri, 21 Feb 2025 08:32:52 GMT https://www.biospace.com/press-releases/psilera-inc-atai-life-sciences-announce-licensing-agreement-for-dmt-patent-portfolio https://www.biospace.com/press-releases/silo-pharma-announces-positive-results-for-novel-spc-15-treatment-targeting-stress-related-disorders Tue, 19 Nov 2024 06:30:14 GMT https://www.biospace.com/press-releases/silo-pharma-announces-positive-results-for-novel-spc-15-treatment-targeting-stress-related-disorders https://www.biospace.com/press-releases/silo-pharma-announces-completion-of-fda-pre-ind-meeting-to-advance-development-of-spc-15-for-treatment-of-ptsd Tue, 10 Sep 2024 11:14:11 GMT https://www.biospace.com/press-releases/silo-pharma-announces-completion-of-fda-pre-ind-meeting-to-advance-development-of-spc-15-for-treatment-of-ptsd https://www.biospace.com/quantum-research-group-survey-reports-investor-insights-about-psychedelic-stocks Mon, 05 Aug 2024 14:00:02 GMT https://www.biospace.com/quantum-research-group-survey-reports-investor-insights-about-psychedelic-stocks https://www.biospace.com/purminds-chief-scientific-officer-to-speak-at-the-4th-annual-psychedelic-therapeutics-and-drug-development-conference PurMinds NeuroPharma ("PurMinds™" or the "Company"), a clinical-stage neuroscience company focused on advancing a robust pipeline of small molecules, psychedelic compounds, and other modalities for the treatment of neurological and neurodegenerative disorders Tue, 21 May 2024 14:40:59 GMT https://www.biospace.com/purminds-chief-scientific-officer-to-speak-at-the-4th-annual-psychedelic-therapeutics-and-drug-development-conference